Chlamydia psittaci is an obligate intracellular bacteria that causes respiratory disease in poultry and humans. Currently, there are no licensed vaccines against chlamydial infection in humans. The transmembrane head protein CPSIT 0846 of C. psittaci is a putative member of the larger Inc protein family. In this study, we investigated immunogenicity and protective efficacy of the recombinant CPSIT 0846 protein in BALB/c mice. Mice immunized with CPSIT 0846 developed strong T-lymphocyte responses that were recalled by the immunogen CPSIT 0846 in an in vitro restimulation assay. These T cells displayed a strong Th1-biased cytokine profile with high levels of IFN-γ . At the same time, a strong humoral immune response was also detected in the immunized mice with high titers of Chlamydia psittaci-specific serum IgG antibodies. More importantly, the robust immune responses correlated well with significantly reduced chlamydial burden and inflammatory pathology in the mouse lungs upon an airway challenge infection. The above results together suggest that the CPSIT 0846 protein may be a potential vaccine candidate antigen for inducing protection against C. psittaci infection and disease in the airway.
INTRODUCTION
Chlamydia psittaci is an obligate intracellular Gram-negative bacteria that belongs to the Chlamydiaceae family, and it causes a primarily avian respiratory disease in pet birds and poultry (Andersen and Vanrompay 2000; Hotzel et al. 2004; Read et al. 2013; Knittler and Sachse 2015) . Chlamydia psittaci infection in humans may result in psittacosis, leading to high morbidity and mortality (Smith et al. 2005) . The bacterium has a characteristic biphasic life cycle, which consists of metabolically inactive infectious elementary bodies (EBs) and metabolically active non-infectious reticulate bodies (RBs). EBs enter host cell and occupy vacuoles called inclusions (Abdelrahman and Belland 2005) . During the intracellular replication, the organisms both require biosynthetic precursors and energy from the infected host cells and modulate cellular responses including the host apoptosis.
Despite the fact that effective antibiotic treatment is available, prophylactic vaccination is the most effective approach for preventing asymptomatic infection (Igietseme, Eko and Black 2011) . However, there is no licensed vaccine against chlamydial infection in humans. Thus, developing an effective vaccine for preventing and controlling chlamydial infection is urgently needed (Huston et al. 2012) .
All chlamydial species have evolved the coding capacity for core components of a type III secretion (T3S) apparatus (Peters et al. 2007) , T3S can directly deliver specific antihost effector proteins into the cytoplasm of an eukaryotic cell. An important family of T3S effectors is localized in the inclusion membrane called inclusion membrane (Inc) proteins. Members of the family display little common sequence similarity, but share a very large (60-80 amino acid residues) bilobed hydrophobic domain (Bannantine et al. 2000) . The C. psittaci Inc A and Inc B have been predicted computationally as T3S effectors (Beeckman et al. 2008 ) that may play important roles in Chlamydia-host interactions and chlamydial pathogenicity (Rockey, Heinzen and Hackstadt 1995; Gupta, Salhan and Mittal 2009) .
The transmembrane head (TMH) family proteins share a paired N-terminal transmembrane domain followed by alphahelical coiled-coil regions, and putatively belonging to the larger Inc protein family. In general, Inc family proteins may play important roles in modifying chlamydial environment and maintaining inclusion vacuole (Read et al. 2000) . The Chlamydophila felis CF0218 was predicted as a TMH family protein with bilobed hydrophobic motif at its N-terminus. CF0218 has been considered as a diagnostic antigen for detecting C. felis infection (Ohya et al. 2008) . In C. psittaci, the tmh locus can encode eight coding sequences, and the TMH protein CPSIT 0846 was identified as possible T3S effectors by computational prediction approaches (Voigt, Schofl and Saluz 2012) . CPSIT 0846 is localized within the inclusion membrane of C. psittaci-infected cells, which can induce the production of inflammatory cytokines such as IL-6, IL-1β and TNF-α in THP-1 cells. Furthermore, CPSIT 0846 was reactive with antiserum from C. psittaciinfected hosts (Wu et al. 2016) . Thus, in the current study, we expressed CPSIT 0846 as a recombinant protein and evaluated the immunogenicity and protection efficacy of the recombinant CPSIT 0846. We found that immunization with CP-SIT 0846 induced robust immune responses that correlated with protection against challenge infection with C. psittaci infection in the airway.
MATERIALS AND METHODS

Chlamydial organisms
Chlamydia psittaci 6BC (ATCC VR-125) was propagated and purified as previously described (Mitchell et al. 2009) . Briefly, C. psittaci EBs were grown in HeLa 229 cell (ATCC VR-125) monolayers, and purified by density gradient centrifugation as previously described and stored at -80
• C (Mukhopadhyay et al. 2004 ).
Infectious EB titer was expressed as inclusion forming unit/ml (IFU/ml).
Cloning, expressing and purifying recombinant protein CPSIT 0846
The DNA fragment coding for CPSIT 0846 (GenBank accession no. NC 015470) was amplified by polymerase chain reaction (PCR) from C. psittaci 6BC genomic DNA as template and forward primer [5 -CGCGGATCCATGACAACTAGTCCTGTGAATA-3 (BamHI)] and reverse primer [5 -TTTTCC-TTTTGCGGCCGCTCAAACTGTCTTAATTGATTTTG-3 (NotI)]. The PCR product was cloned into pET-30a precut with BamHI and NotI to construct the recombinant plasmid pET-30a-CPSIT 0846. Fidelity of the construction was confirmed by DNA sequence analysis. The pET-30a-CPSIT 0846 plasmid was transformed into Escherichia coli BL21 for expressing His-tagged CPSIT 0846, which was induced with isopropyl-β -D-thiogalactoside (IPTG). The His-fusion protein was purified using Ni-nitrilotriacetic acid beads (QIAGEN Inc., Germany) according to the manufacturer's instructions. The purity was monitored using Commassie blue-stained SDS gel and validated using western blotting with pooled sera from immunized mice or a mouse anti-His-tag monoclonal antibody and analyzed by western blotting with pooled sera gained from experimental group immunized mice or an anti-His-tag mouse monoclonal antibody. The recombinant protein CPSIT 0846 was concentrated with an Amicon Ultra-15 unit (Millipore, Billerica, MA, USA), and endotoxins were removed with a polymyxin B cartridge (Sigma, St. Louis, MO, USA). The concentrations of the pure His-tagged proteins were determined by using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA).
Mouse immunization and infection
Special pathogen-free female BALB/c mice aged 6 weeks old were obtained from Hunan SJA Laboratory Animal Co. Ltd, and were divided into three groups (12 mice per group): one for intraperitoneal (i.p.) injection with purified fusion protein (immunization group), the second for i.p. injection with phosphatebuffered saline (PBS; blank control group) and the third for injection with ovalbumin (negative antigen control group). All were injected three times with 2-week interval. Both CPSIT 0846 and ovalbumin were emulsified in complete Freund's adjuvant for the initial injection and incomplete Freund's adjuvant (all adjuvants were from Sigma) for the second and third injection. For each injection, 30 μg of CPSIT 0846 or ovalbumin protein emulsified in Freund's adjuvant in a total volume of 0.1 ml was used. Two weeks after the third immunization, serum and spleen samples were collected from the mice for measuring antibody titers and lymphocyte responses. In parallel groups, on day 14 after the last immunization, mice were challenged intranasally (i.n.) with 10 5 IFU of C. psittaci EBs in 30 μl of sucrose-phosphateglutamicacid buffer under the ether anesthesia (Bode et al. 2012; Dutow et al. 2014) . Mice were weighed prior to, and 3, 6 and 10 after the challenge infection. On day 10, all mice were sacrificed for monitoring both C. psittaci titers and pathology in the lung. For titrating C. psittaci live organisms, lung homogenates were serially diluted and inoculated onto HeLa 229 cell monolayers. Thirty hours after the inoculation, the infected cells were processed for immunofluorescence detection of C. psittaci inclusions as described previously (He et al. 2015) . The number of live organisms recovered from each lung was calculated based on the number of inclusion counted and the area counted and dilution of the tissue homogenates and expressed as IFUs. All animal procedures and treatments were approved by the Animal Welfare and Ethics Committee of the University of South China and were performed in accordance with the regulations of the institution.
Immuofluorescence assay
HeLa 229 cell monolayers grown on sterile glass coverslips were infected with collected lung homogenates and incubated for 30 h. The infected cells were fixed with 4% paraformaldehyde for 30 min, and permeabilized with 0.3% (v/v) Triton-100 for 10 min, and blocked with complete Dulbecco's modified Eagle medium (HyClone, USA) containing 10% fetal bovine serum (Invitrogen, Grand Island, NY, USA) for 2 h. After washing, the infected cells were inoculated with rabbit anti-C. psittaci 6BC antibody for 2 h at 37
• C. After being washed three times with PBS, the cell samples were inoculated with Cy2-labeled (green fluorescence) goat anti-rabbit immunoglobulin G (IgG) (Jackson ImmunoResearch Laboratories, USA) and 4, 6-diamidine-2-phenylindole dihydrochloride (Sigma) for 1 h at 37
• C. All images were obtained under fluorescence microscopy. The inclusion bodies in the cells were counted five random fields per coverslip under a microscope at 400-fold magnification to calculate the IFU/mL for each sample.
Analysis of antibody levels
The levels of C. psittaci-specific IgG, IgA and IgG subtype antibodies in serum were detected using Ready-SET-Go! kits (eBioscience Inc., CA, USA) according to the manufacturer's instructions. Briefly, microtiter plates were coated with recombinant protein CPSIT 0846 (10 μg ml −1 ) in a sodium bicarbonate buffer (pH 9.5) at 4
• C overnight. The plates were washed with PBS containing 0.05% Tween-20 (PBST) three times and blocked with blocking buffer and incubated at 37
• C for 1 h. After further washes, a total of 100 μl of 1: 10000 dilutions of serum was added in duplicate to each well for 1 h at 37 • C, respectively. After washing four times with PBST, 50 μl of horseradish peroxidaseconjugated goat anti-mouse immunoglobulin G (IgG), IgG1, IgG2a, IgG2b, IgG3 and IgA antibodies was added to each serum well at 37
• C for 1 h, respectively. After washing again, the plates were added 3, 3 , 5, 5 -tetramethylbenzidine substrate with 100 μl/well and incubated at room temperature for 15 min. The reaction was stopped by 100 μl of eBioscience Stop Solution in each well, and the absorbance was measured at 450 nm.
Measurement of cytokines
On day 14 after the final immunization, spleens were collected from each group and prepared single-cell suspensions. Cells were cultured in duplicate and stimulated for 48 h in vitro with recombinant protein CPSIT 0846 (10 μg) on culture plate. Supernatants were harvested from the culture wells, and assessed for IFN-γ and IL-4 levels using Ready-SET-Go! kits (eBioscience) according to the instructions provided by the manufacturer.
Splenocyte proliferation assay
Lymphocyte proliferation was assessed by Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan) from splenic cells stimulated as described above. Briefly, 20 μl (5 mg ml −1 ) of CCK-8 was added to the cell suspension in each well for 4 h and the optical density at 450 nm (OD 450 ) of each well was determined, and expressed in terms of Stimulation Index (SI).
Histopathology of the lung tissues
Lungs of three mice from each group were harvested 10 days after challenge. The lungs were fixed with 10% neutral buffered formalin, and embedded in paraffin and were sectioned and stained with hematoxylin-eosin (H&E). Besides, streptavidinperoxidase (S-P) immunohistochemistry was performed by an UltraSensitive SP (Rabbit) IHC Kit (Maixin, China) for the detection of C. psittaci. Briefly, the sections were processed with a peroxidase blocking solution to inhibit background staining using endogenous peroxidase. The lung tissues were stained with a rabbit anti-C. psittaci 6BC as primary antibody, and biotin-labeled goat anti-rabbit as secondary antibody. Chromogen DAB Solution used as substrate. The slides were counterstained using hematoxylin. Normal rabbit serum was served as negative control.
Statistical analyses
Using SPSS 18.0 software, statistical comparisons between the groups for antibody, cytokine and bacterial burden levels were carried out by one-way analysis of variance with the StudentNewman-Keuls test. P < 0.05 were considered statistically significant.
RESULTS
Immunization with recombinant protein CPSIT 0846 induces Th1 cytokine-dominated cellular immune response
The 447 bp fragment of CPSIT 0846 was amplified, cloned into the pET-30a vector and expressed as a His-tagged protein in Escherichia coli BL21 (Fig. 1) . When the recombinant CPSIT 0846 protein was used to immunize BALB/c mice, a strong T-lymphocyte response was detected (Fig. 2) . Splenocytes taken from the immunized mice responded to restimulation with recombinant CP-SIT 0846 while those from control mice failed to do so. When the splenocytes were measured for cytokine production using ELSA, significantly higher levels of IFN-γ were detected in the immunized mice. The levels of IFN-γ from supernatants of splenocytes stimulated with recombinant CPSIT 0846 protein were significantly higher in mice immunized with recombinant CPSIT 0846 protein, compared with their respective control groups immunized with PBS or ovalbumin (P < 0.05); The levels of IL-4 were very low in all groups (Fig. 3) .
Immunization with recombinant protein CPSIT 0846 induces strong anti-Chlamydia psittaci antibody responses
Two weeks after the last immunization, serum samples were collected and the humoral immune response was evaluated by ELISA assay. It is very clear that recombinant protein CPSIT 0846 immunization induced notably higher levels of IgG and IgA antibodies than ovalbumin-or PBS-immunized mice (P < 0.05) (Fig. 4) . We subsequently determined the levels of the serum IgG subtypes in CPSIT 0846-immunized mice and compared to . SI of spleen cells from different mice. Two weeks after the last immunization, mice were euthanized, and spleens were tested for a proliferation response by CKK-8. The asterisks show that there are significant differences in the proliferation response of spleen cells between PBS-and ovalbumin-or CP-SIT 0846-immunized mice. Means ± SD of the results from six individual mouse spleens in three independent experiments ( * * P < 0.05).
PBS-or ovalbumin-immunized mice. The levels of IgG1, IgG2a, IgG2b and IgG3 antibodies induced by recombinant protein CP-SIT 0846 immunization were significantly higher than in those of the control mice (Fig. 4) . 
Immunization with recombinant protein CPSIT 0846 induces protection against Chlamydia psittaci challenge infection in the lung
All mice maintained similar body weight after airway challenge infection regardless of the proteins used for immunization (data not shown), which might reflect the sublethal dose infection that did not cause any significant systemic toxicity. However, when the live organisms recovered from lung tissue homogenates were compared, the CPSIT 0846-immunized Figure 5 . Chlamydia psittaci titres in the lungs of CPSIT 0846 immunized mice after the C. psittaci challenge. Two weeks after the final immunization, and followed by challenge with C. psittaci. On day 10 post-infection, mice were sacrificed. Chlamydia psittaci load in mice lung was assessed by indirect immunofluorescence. The asterisks show that there are significant differences in the C. psittaci load of lungs between PBS-immunized and ovalbumin-or CPSIT 0846-immunized mice. Means ± SD of C. psittaci titres (IFU/lung) in the lung homogenates results from five individual mouse lungs in three independent experiments ( * P < 0.05).
mice displayed the lowest level of C. psittaci burden (Fig. 5) . The reduced lung burden also correlated with significantly decreased inflammatory pathologies in the lungs. Serious lung pathological lesions were observed in PBS-immunized (Fig. 6A ) or ovalbumin-immunized (Fig. 6B) mice. Interstitial pneumonia was characterized by large numbers of inflammatory infiltrates of polymorphonuclear leukocytes, mononuclear cells, alveolar interstitial thickening and hemorrhage. The lung tissue pathology lesions of mice immunized with recombinant protein CPSIT 0846 were not as severe as in other mice (Fig. 6C) . Assessment of lung tissue sections by S-P immunohistochemistry displayed that C. psittaci-infected mice immunized with recombinant CPSIT 0846 protein have lower pathological damages. In addition, immunization of mice with recombinant protein CPSIT 0846 elicited a significantly lower chlamydial burden (brown granule) compared with that in the control mice (Fig. 7) .
DISCUSSION
Previous studies have demonstrated that Incs can modulate expression of T-cell lineage determinants suggesting their involvement in regulation of immune cells (Gupta et al. 2009b) . Besides, it has been shown that Chlamydia trachomatis (CT) Inc B and Inc C induced humoral and cell-mediated immune responses in CTinfected women (Gupta et al. 2009a) . Another study showed that antibodies against CT Inc B and Inc C were general in CT-positive women diagnosed with infertility or cervicitis (Gupta, Salhan and Mittal 2009 ). The TMH protein CPSIT 0846 of Chlamydia psittaci putatively belong to the larger Inc protein family, which is inclusion membrane protein (Read et al. 2000; Wu et al. 2016) . Therefore, we predict that CPSIT 0846 may have similar roles to those of Inc protein from other species as described above. In the current study, we successfully cloned CPSIT 0846 gene, expressed recombinant protein CPSIT 0846 in Escherichia coli BL21 and purified the protein by His-tag affinity chromatography. The size of the recombinant CPSIT 0846 was slightly larger than predicted, possibly due to difference of protein modification in E. coli expression system or the His-tag at the N-terminus. The CPSIT 0846 reacted with sera gained from CPSIT 0846-immunized mice by immunoblotting experiments. It was displayed that recombinant CPSIT 0846 could elicit the production of specific antibodies in mice.
We set out to explore whether a specific immune response to recombinant CPSIT 0846 can protect against C. psittaci infection. The fusion protein showed strong immunogenicity due to its capability to produce high levels of specific antibodies and cellular immune responses in CPSIT 0846-immunized mice. The results suggest that the recombinant CPSIT 0846 has the potential for developing vaccine to prevent chlamydial infection. The role of specific antibodies in mice chlamydial infections has evolved from becoming focus of protection immunity and vaccine development (Morrison and Morrison 2001; Shaw et al. 2011) . The data demonstrated that mice immunized with recombinant CPSIT 0846 showed high titers of serum anti-CPSIT 0846 total antibody IgG, IgG1, IgG2a, IgG2b and IgG3. Previous studies have shown that specificity increasing the production of the IgG subtypes reflects the type of Th-cell responses, i.e., that Th1 response facilitates IgG2a production and Th2 response induces IgG1 and IgG2b expression (Barry and Johnston 1997) . Here, we demonstrated that the recombinant CPSIT 0846 protein mainly induced Th2 response with the order of specific antibody production of IgG2b > IgG1 > IgG2a in CPSIT 0846-immunized mice (Fig. 4) . Previous studies have shown that IgA in neonates against pulmonary chlamydial infection induced respiratory pathological sequelae observed later in life (Lanka et al. 2016) . Besides, it has been shown that the IgA plays an important role in the mucosal immunity for preventing chlamydial infection (Eko et al. 2004) . The level of IgA antibody was distinctly increased in CPSIT 0846-immunized mice. Therefore, this showed that recombinant CPSIT 0846 immunization elicited a strong humoral response in mucosal compartments.
In this study, it was showed that T-cell proliferative responses from mice immunized with recombinant CPSIT 0846 were increased compared to those mice immunized with PBS or ovalbumin. Because immunity against chlamydial infection is based primarily on the role of Th1 cells (Morrison and Caldwell 2002; Faal et al. 2005) , CD4 + Th1 cells and CD4 + Th1-induced cytokines such as IFN-γ and IL-12 play vital roles in inducing strong protective immunity against chlamydial infection (Loomis and Starnbach 2002; Yang 2003) . IFN-γ is thought to play an important role in clearance of chlamydial infection (Rottenberg, Gigliotti-Rothfuchs and Wigzell 2002; Gracey et al. 2015) . It has been displayed that the activated Th1 cells increase the secretion of IFN-γ and IL-2, while the activated Th2 cells enhance the secretion of IL-4 and IL-5 (Morrison et al. 2000 (Morrison et al. , 2011 . Based on the test of IFN-γ and IL-4 in spleens, our results display that splenocytes from CPSIT 0846-immunized mice show both increased IFN-γ generation and minimal IL-4 generation in vitro (Fig. 3) , indicating that Th1 immune response was strongly elicited in CPSIT 0846-immunized mice. In addition, 14 days after the last immunization, the mice were challenged with C. psittaci, immunization with recombinant protein CPSIT 0846 significantly reduced chlamydial load and the extent of inflammation in the lungs of infected mice. The above results showed that recombinant CPSIT 0846 protein could induce a sufficiently strong humoral and cellular immune response to offer mice protection efficacy against C. psittaci infection.
In summary, our results demonstrated that recombinant CPSIT 0846 was a novel protective antigen of C. psittaci since it conferred a significant protection efficacy against C. psittaci infection in a murine model. This protection offered by recombinant CPSIT 0846 induced significantly stronger humoral response and the stronger cell-mediated response, i.e. that multiple immunization with recombinant protein CPSIT 0846 resulted in a significantly reduced chlamydial burden and the extent of inflammation in the lungs of mice challenged with C. psittaci. Collectively, these data suggest that CPSIT 0846 protein induces notable protective efficacy against C. psittaci infection in mice, and should guide the future vaccine development of C. psittaci. (Grant No. 2015-351) .
